| Title | A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: An observational prospective study |
|---|---|
| Publication Type | Articolo su Rivista peer-reviewed |
| Year of Publication | 2008 |
| Authors | Novelli, Flavia, Milella M., Melucci E., Di Benedetto A., Sperduti I., Perrone-Donnorso R., Perracchio L., Venturo I., Nisticò C., Fabi A., Buglioni S., Natali P.G., and Mottolese M. |
| Journal | Breast Cancer Research |
| Volume | 10 |
| ISSN | 14655411 |
| Keywords | adult, aged, Antineoplastic Agents, antineoplastic hormone agonists and antagonists, article, Biological, Breast Neoplasms, breast tumor, cancer invasion, Carcinoma, chemistry, classification, comparative study, disease course, Disease Progression, Drug Resistance, epidermal growth factor receptor 2, erbB-2, estrogen, estrogen receptor beta, Estrogens, Female, Hormonal, Hormone-Dependent, human, Humans, isoprotein, Ki 67 antigen, Ki-67 Antigen, lymph node metastasis, Lymphatic Metastasis, Middle Aged, Mortality, Neoplasm, Neoplasm Invasiveness, Neoplasms, Pathology, physiology, Progesterone, progesterone receptor, prognosis, Prospective Studies, prospective study, protein bcl 2, Protein Isoforms, protein p53, Proto-Oncogene Proteins c-bcl-2, Receptor, Receptors, tumor marker, Tumor Markers, Tumor Suppressor Protein p53 |
| Abstract | Estrogen receptor-alpha (ER-α) and progesterone receptor (PgR) are consolidated predictors of response to hormonal therapy (HT). In contrast, little information regarding the role of estrogen receptor-beta (ER-β) in various breast cancer risk groups treated with different therapeutic regimens is available. In particular, there are no data concerning ER-β distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN).Methods: We conducted an observational prospective study using immunohistochemistry to evaluate ER-β expression in 936 breast carcinomas. Associations with conventional biopathological factors and with molecular subtypes were analyzed by multiple correspondence analysis (MCA), while univariate and multivariate Cox regression analysis and classification and regression tree analysis were applied to determine the impact of ER-β on disease-free survival in the 728 patients with complete follow-up data.Results: ER-β evenly distributes (55.5%) across the four molecular breast cancer subtypes, confirming the lack of correlation between ER-β and classical prognosticators. However, the relationships among the biopathological factors, analyzed by MCA, showed that ER-β positivity is located in the quadrant containing more aggressive phenotypes such as HER2 and TN or ER-α/PgR/Bcl2-tumors. Kaplan-Meier curves and Cox regression analysis identified ER-β as a significant discriminating factor for disease-free survival both in the node-negative LA (P = 0.02) subgroup, where it is predictive of response to HT, and in the node-positive LB (P = 0.04) group, where, in association with PgR negativity, it conveys a higher risk of relapse.Conclusion: Our data indicated that, in contrast to node-negative patients, in node-positive breast cancer patients, ER-β positivity appears to be a biomarker related to a more aggressive clinical course. In this context, further investigations are necessary to better assess the role of the different ER-β isophorms. © 2008 Novelli et al.; licensee BioMed Central Ltd. |
| Notes | cited By 57 |
| URL | https://www.scopus.com/inward/record.uri?eid=2-s2.0-59449088889&doi=10.1186%2fbcr2139&partnerID=40&md5=99b999108a6e51cf4087e0e05531634f |
| DOI | 10.1186/bcr2139 |
| Citation Key | Novelli2008 |
